Marksans Pharma Ltd (BOM:524404) reported a 16% sequential revenue growth in Q2 FY26, driven by improved demand and operational execution. The US market showed robust performance with a 27% ...
Earnings call Marksans Pharma delivered a strong Q2 FY26 with 12.2% YoY revenue growth and a 44% sequential EBITDA increase, driven by robust U.S. performance and operational efficiency. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results